Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) has a cash flow conversion efficiency ratio of 0.057x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (TL180.45 Million ≈ $4.04 Million USD) by net assets (TL3.17 Billion ≈ $71.04 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Meditera Tibbi Malzeme Sanayi ve Ticaret net asset quality index to measure how much of total assets are equity-financed.
Meditera Tibbi Malzeme Sanayi ve Ticaret AS - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Meditera Tibbi Malzeme Sanayi ve Ticaret AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Meditera Tibbi Malzeme Sanayi ve Ticaret cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Meditera Tibbi Malzeme Sanayi ve Ticaret AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Meditera Tibbi Malzeme Sanayi ve Ticaret AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nam Liong Global Corp
TWO:5450
|
0.048x |
|
Sambu Const
KO:001470
|
-0.064x |
|
Northwest Copper Corp
V:NWST
|
-5.572x |
|
Coxon Precise Industrial Co Ltd
TW:3607
|
-0.017x |
|
Golan Plastic
TA:GLPL
|
0.112x |
|
INTER RAO Lietuva AB
WAR:IRL
|
0.213x |
|
Zomedica Pharmaceuticals Corp
NYSE MKT:ZOM
|
-0.050x |
|
Thai Reinsurance Public Company Limited
BK:THRE
|
0.050x |
Annual Cash Flow Conversion Efficiency for Meditera Tibbi Malzeme Sanayi ve Ticaret AS (2018–2025)
The table below shows the annual cash flow conversion efficiency of Meditera Tibbi Malzeme Sanayi ve Ticaret AS from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see MEDTR company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | TL2.93 Billion ≈ $65.61 Million |
TL435.35 Million ≈ $9.75 Million |
0.149x | -44.31% |
| 2024-12-31 | TL2.93 Billion ≈ $65.52 Million |
TL780.69 Million ≈ $17.49 Million |
0.267x | -28.82% |
| 2023-12-31 | TL2.14 Billion ≈ $47.85 Million |
TL801.02 Million ≈ $17.94 Million |
0.375x | +6421.15% |
| 2022-12-31 | TL887.08 Million ≈ $19.87 Million |
TL5.10 Million ≈ $114.23K |
0.006x | -91.07% |
| 2021-12-31 | TL569.37 Million ≈ $12.75 Million |
TL36.64 Million ≈ $820.70K |
0.064x | -80.92% |
| 2020-12-31 | TL217.15 Million ≈ $4.86 Million |
TL73.26 Million ≈ $1.64 Million |
0.337x | +113.28% |
| 2019-12-31 | TL126.49 Million ≈ $2.83 Million |
TL20.01 Million ≈ $448.12K |
0.158x | -76.66% |
| 2018-12-31 | TL108.11 Million ≈ $2.42 Million |
TL73.26 Million ≈ $1.64 Million |
0.678x | -- |
About Meditera Tibbi Malzeme Sanayi ve Ticaret AS
Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi manufactures and sells medical devices in Turkey. The company offers two-way and single-line Infusion Systems; Chemotherapy Preparation and Administration Systems, such as medoconco automated drug preparation, diana semi-automatic drug dispensing, and ICU medical chemotherapy drug delivery systems; and respiratory systems products, includin… Read more